Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Rhea-AI Summary
Aspire Biopharma (Nasdaq: ASBP) received a notice from the Nasdaq Hearings Panel granting an extension to continue its Nasdaq listing, subject to conditions after the Company's transfer to the Nasdaq Capital Market.
The company will transfer its common stock listing effective at market open on December 15, 2025, retain the symbol ASBP, and must demonstrate compliance with the Bid Price Rule (Rule 5550(a)(2)) by January 30, 2026 and the Equity Rule (Rule 5550(b)(1)) by February 17, 2026. Management said it expects to cure the bid-price and market-value deficiencies and is working to recapitalize the balance sheet.
Positive
- Nasdaq Hearings Panel granted an extension to continue listing
- Listing transfer to Nasdaq Capital Market effective Dec 15, 2025
- Ticker ASBP unchanged; trading stated as unaffected
Negative
- Must meet Bid Price Rule by Jan 30, 2026
- Must meet Equity Rule by Feb 17, 2026
- Company currently has bid-price and market-value deficiencies
Market Reaction 15 min delay 5 Alerts
Following this news, ASBP has gained 22.21%, reflecting a significant positive market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.12. This price movement has added approximately $2M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus 1 Up 1 Down
ASBP was up 22.51% while close peers showed mixed moves (e.g., XCUR up 8.55%, CRIS down 8.66%, ICU down 8.12%), indicating a company-specific reaction to the Nasdaq compliance extension.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Business update | Positive | +2.5% | Q3 2025 update with positive bioavailability, IP, and FDA feedback. |
| Dec 02 | Regulatory update | Positive | +1.1% | Pre-IND meeting request to FDA for sublingual aspirin product. |
| Nov 26 | Hiring announcement | Positive | +2.8% | Addition of experienced scientific leader to support platform development. |
| Nov 06 | Partnership outreach | Positive | -23.9% | Meetings with global pharma on sublingual aspirin despite positive study data. |
| Oct 06 | IP protection | Positive | +0.3% | Filing omnibus patent application for sublingual drug delivery platform. |
Recent news has generally seen modestly positive price alignment, with one sharp selloff on partnership discussions despite positive clinical data.
Over the last few months, Aspire Biopharma has focused on strengthening its sublingual drug delivery platform and regulatory path. Key items include an omnibus patent filing on Oct 06, 2025, partnership outreach at CPHI Frankfurt, clinical and regulatory updates including Pre-IND interactions with FDA, and a Q3 2025 business update. Most prior announcements produced small positive price moves, aside from a notable decline on partnership-related news, providing context for today’s compliance-focused update.
Market Pulse Summary
The stock is surging +22.2% following this news. A strong positive reaction aligns with the relief implied by Nasdaq granting more time to regain listing compliance. Historically, Aspire’s news flow has often produced modest positive moves, with one notable negative outlier on partnership discussions. Investors reviewing this development may contrast the compliance extension with the company’s tight liquidity and going-concern disclosures in recent filings, alongside potential dilution from existing financing arrangements.
Key Terms
nasdaq capital market regulatory
nasdaq global select market regulatory
AI-generated analysis. Not financial advice.
ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received notice (the "Notice") on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions upon transfer of its common stock to The Nasdaq Capital Market, including demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") on or before January 30, 2026 and with Listing Rule 5550(b)(1) (the "Equity Rule") on or before February 17, 2026.
In connection with the Notice, the Company will transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market effective as of the opening of business on December 15, 2025. The Company's common stock will continue to be traded under the symbol "ASBP" and trading of its common stock will be unaffected by this transfer.
"We believe the extension granted by the Nasdaq Hearings Panel will allow us to finish executing on our plan to regain compliance with Nasdaq's requirements," said Kraig Higginson, Interim CEO of Aspire. "We expect the Company will cure the bid price and market value of listed shares deficiencies within the required time frame. We are undertaking substantial steps in an effort to recapitalize the balance sheet and set up the Company to deliver long term value to our shareholders."
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Aspire Biopharma (ASBP) announce about its Nasdaq listing on December 12, 2025?
What compliance deadlines must ASBP meet after the transfer to Nasdaq Capital Market?
Will ASBP trading be interrupted by the transfer to the Nasdaq Capital Market?
What happens if ASBP fails to regain compliance by the deadlines?
Who is Aspire's interim CEO and what did he say about regaining compliance for ASBP?
